A
Aleš Linhart
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 371
Citations - 36568
Aleš Linhart is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Fabry disease & Medicine. The author has an hindex of 50, co-authored 333 publications receiving 30467 citations. Previous affiliations of Aleš Linhart include University Hospital of Wales & Charles University in Prague.
Papers
More filters
Journal ArticleDOI
Hyperinvasive approach to out-of hospital cardiac arrest using mechanical chest compression device, prehospital intraarrest cooling, extracorporeal life support and early invasive assessment compared to standard of care. A randomized parallel groups comparative study proposal. “Prague OHCA study”
Jan Belohlavek,Karel Kucera,Jiri Jarkovsky,Ondrej Franek,Milana Pokorna,Jiri Danda,Roman Skripsky,Vít Kandrnal,Martin Balik,Jan Kunstyr,Jan Horák,Ondrej Smid,Jaroslav Valasek,Vratislav Mrazek,Zdenek Schwarz,Aleš Linhart +15 more
TL;DR: A prospective randomized study comparing prehospital intraarrest hypothermia combined with mechanical chest compression device, intrahospital ECLS and early invasive investigation and treatment in all patients with OHCA of presumed cardiac origin compared to a standard of care in refractory OHCA is performed.
Journal ArticleDOI
European expert consensus statement on therapeutic goals in Fabry disease.
Christoph Wanner,Michael Arad,Ralf Baron,Alessandro P. Burlina,Perry M. Elliott,Ulla Feldt-Rasmussen,Victor Fomin,Dominique P. Germain,Derralynn Hughes,Ana Jovanovic,Ilkka Kantola,Aleš Linhart,Renzo Mignani,Lorenzo Monserrat,Mehdi Namdar,Albina Nowak,João Paulo Oliveira,Alberto Ortiz,Maurizio Pieroni,Marco Spada,Anna Tylki-Szymańska,Camilla Tøndel,Miguel Viana-Baptista,Frank Weidemann,Max J. Hilz +24 more
TL;DR: The consensus therapeutic goals and proposed patient management algorithm take into account the need for early disease-specific therapy to delay or slow the progression of disease as well as non-specific adjunctive therapies that prevent or treat the effects of organ damage on quality of life and long-term prognosis.
Journal ArticleDOI
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Alberto Ortiz,Ademola K. Abiose,Daniel G. Bichet,Gustavo Cabrera,Joel Charrow,Joel Charrow,Dominique P. Germain,Robert J. Hopkin,Ana Jovanovic,Aleš Linhart,Sonia S. Maruti,Michael Mauer,João Paulo Oliveira,Manesh R. Patel,Juan Politei,Stephen Waldek,Christoph Wanner,Han Wook Yoo,David G. Warnock +18 more
TL;DR: Adult patients with Fabry disease had decreased incidence of severe clinical events after 6’months treatment with agalsidase β 1 mg/kg every 2 weeks, compared to the expected increased incidence with time.
Journal ArticleDOI
Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study.
Martin Penicka,Jan Horák,Kobylka P,Robert Pytlik,Tomas Kozak,Otakar Belohlavek,Otto Lang,Hana Skalická,Stanislav Šimek,Tomáš Paleček,Aleš Linhart,Michael Aschermann,Petr Widimsky +12 more
TL;DR: One-third of patients with ST-segment elevation myocardial infarction, usually those presenting late, show ongoing left ventricular remodeling and poor clinical outcome despite primary percutaneous coronary intervention (PCI).
Journal ArticleDOI
Coronary versus carotid blood flow and coronary perfusion pressure in a pig model of prolonged cardiac arrest treated by different modes of venoarterial ECMO and intraaortic balloon counterpulsation.
Jan Bělohlávek,Mikulas Mlcek,Michal Huptych,Tomáš Svoboda,Štěpán Havránek,Petr Ostadal,Tomáš Bouček,Tomas Kovarnik,František Mlejnský,Vratislav Mrazek,Marek Bělohlávek,Michael Aschermann,Aleš Linhart,Otomar Kittnar +13 more
TL;DR: In a pig model of CA, both FF and FS ECMO assure adequate brain perfusion and oxygenation, and FF ECMO offers better CoBF thanFS ECMO, which increases CoPP over time.